Abstract
A pEGylated glucagon-like peptide-1 (GLP-1) agonist and glucagon antagonist hybrid peptide was engineered as a potential treatment for type 2 diabetes. To support preclinical development of this PEGylated dual-acting peptide for diabetes (DAPD), we developed a reproducible method for PEGylation, purification, and analysis. Optimal conditions for site-specific PEGylation with 22 and 43 kDa maleimide-polyethylene glycol (maleimide-PEG) polymers were identified by evaluating pH, reaction time, and reactant molar ratio parameters. A 3-step purification process was developed and successfully implemented to purify PEGylated DAPD and remove excess uncoupled PEG and free peptide. Five lots of 43 kDa PEGylated DAPD with starting peptide amounts of 100 mg were produced with overall yields of 53% to 71%. Analytical characterization by N-terminal sequencing, amino acid analysis, matrix-assisted laser desorption/ionization mass spectrometry, and GLP-1 receptor activation assay confirmed site-specific attachment of PEG at the engineered cysteine residue, expected molecular weight, correct amino acid sequence and composition, and consistent functional activity. Purity and safety analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), analytical ion-exchange chromatography, reversed-phase high-performance liquid chromatography, and limulus amebocyte lysate test showed that the final products contained<1% free peptide, <5% uncoupled PEG, and <0.2 endotoxin units per milligram of peptide. These results demonstrate that the PEGylation and purification process we developed was consistent and effective in producing PEGylated DAPD preclinical materials at the 100 mg (peptide weight basis) or 1.2 g (drug substance weight basis) scale.
Keywords: PEGylation, chromatography, GLP-1, glucagon
Full Text
The Full Text of this article is available as a PDF (914.6 KB).
References
- 1.Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology, XXXV: the glucagon receptor family. Pharmacol Rev. 2003;55:167–194. doi: 10.1124/pr.55.1.6. [DOI] [PubMed] [Google Scholar]
- 2.Jelinek LJ, Lok S, Rosenberg GB, et al. Expression cloning and signaling properties of the rat glucagon receptor. Science. 1993;259:1614–1616. doi: 10.1126/science.8384375. [DOI] [PubMed] [Google Scholar]
- 3.Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA. 1992;89:8641–8645. doi: 10.1073/pnas.89.18.8641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hjorth SA, Adelhorst K, Pedersen BB, Kirk O, Schwartz TW. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J Biol Chem. 1994;269:30121–30124. [PubMed] [Google Scholar]
- 5.Roges OA, Baron M, Philis-Tsimikas A. The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management. Expert Opin Investig Drugs. 2005;14:705–727. doi: 10.1517/13543784.14.6.705. [DOI] [PubMed] [Google Scholar]
- 6.Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284:E671–E678. doi: 10.1152/ajpendo.00492.2002. [DOI] [PubMed] [Google Scholar]
- 7.Pan CQ, Buxton JM, Yung SL, et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem. 2006;281:12506–12515. doi: 10.1074/jbc.M600127200. [DOI] [PubMed] [Google Scholar]
- 8.Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug. Discov Today. 2005;10:1451–1458. doi: 10.1016/S1359-6446(05)03575-0. [DOI] [PubMed] [Google Scholar]
- 9.Lee KC, Tak KK, Park MO, et al. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. Pharm Dev Technol. 1999;4:269–275. doi: 10.1081/PDT-100101361. [DOI] [PubMed] [Google Scholar]
- 10.Chowdhury SK, Doleman M, Johnston D. Fingerprinting proteins coupled with polymers by mass spectrometry: investigation of polyethylene glycol-conjugated superoxide dismutase. J Am Soc Mass Spectrom. 1995;6:478–487. doi: 10.1016/1044-0305(95)00190-O. [DOI] [PubMed] [Google Scholar]
- 11.Watson E, Shah B, DePrince R, Hendren RW, Nelson R. Matrix-assisted laser desorption mass spectrometric analysis of a PEGylated recombinant protein. Biotechniques. 1994;16:278–280. [PubMed] [Google Scholar]
- 12.Claus TH, Pan CQ, Buxton JM, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J Endocrinol. 2007;192:371–380. doi: 10.1677/JOE-06-0018. [DOI] [PubMed] [Google Scholar]